TransMedics Revenue and Competitors

Boston, MA USA

Location

#3894

Growjo Ranking

Estimated Revenue & Valuation

  • TransMedics's estimated annual revenue is currently $155.7M per year.(i)
  • TransMedics received $12.5M in venture funding in July 2016.
  • TransMedics's estimated revenue per employee is $351,400
  • TransMedics's total funding is $266M.

Employee Data

  • TransMedics has 443 Employees.(i)
  • TransMedics grew their employee count by 82% last year.

TransMedics's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
VPReveal Email/Phone
3
VP Global Regulatory AffairsReveal Email/Phone
4
VP Abdominal Medical AffairsReveal Email/Phone
5
VP Clinical AffairsReveal Email/Phone
6
SVP, Global Regulatory AffairsReveal Email/Phone
7
ControllerReveal Email/Phone
8
VP Cardiothoracic Clinical DevelopmentReveal Email/Phone
9
VP, Corporate ControllerReveal Email/Phone
10
VP Human ResourcesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.8M393%N/AN/A
#2
$8.5M343%N/AN/A
#3
$3M12-29%N/AN/A
#4
$5630M7477-11%$450MN/A
#5
$4.5M186%N/AN/A
#6
$7.2M5727%$29.6MN/A
#7
$14.3M57-12%N/AN/A
#8
$2.3M186%$44MN/A
#9
$40.7M162-1%N/AN/A
#10
$45.7M182-5%N/AN/A
Add Company

What Is TransMedics?

TransMedics Inc. is the world's leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. The company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. The OCS Lung and OCS Heart systems are CE-marked and in commercial use outside the US, and are currently being reviewed by the FDA for U.S. market access. The OCS Liver is in an FDA pivotal trial (The OCS Liver PROTECT Trial) in the United States and a CE-Mark trial in (The REVIVE Trial) in Europe.

keywords:Biotechnology,Hardware,Healthcare,Medical Devices,Pharmaceuticals

$266M

Total Funding

443

Number of Employees

$155.7M

Revenue (est)

82%

Employee Growth %

N/A

Valuation

N/A

Accelerator

TransMedics News

2022-04-20 - FDA approves Transmedics OCS Heart organ transplant system

TransMedics (Nasdaq:TMDX) announced today that it received FDA premarket approval (PMA) for its OCS Heart system. FDA PMA allows Andover,...

2022-04-20 - TransMedics gets FDA approval for expanded use of OCS ...

TransMedics Group (NASDAQ:TMDX) said the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) to its OCS Heart System...

2022-04-20 - TransMedics Receives FDA PMA Approval of OCS™ DCD Heart Indication

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in...

2021-11-10 - TransMedics Reports Third Quarter 2021 Financial Results

ANDOVER, Mass., Nov. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended Septe ...

2021-11-04 - TransMedics Announces Positive Top Line Results From the U.S. Randomized OCS DCD Heart Trial

ANDOVER, Mass., Nov. 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced positive topline results from its OCS donors ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$101.3M4638%N/A
#2
$133.4M508-14%N/A
#3
$35M5489%N/A
#4
$125.6M558N/AN/A
#5
$136.1M6054%N/A

TransMedics Funding

DateAmountRoundLead InvestorsReference
2004-01-14$26.3MBArticle
2006-03-15$29.8MC3i GroupArticle
2007-03-14$25.0MDArticle
2009-07-18$2.5MUndisclosedArticle
2009-12-10$0.0MUndisclosedArticle
2010-03-05$36.0MUndisclosedFoundation Capital , Kleiner Perkins Caufield & ByeArticle
2012-11-28$36.0MUndisclosedAbrams CapitalArticle
2015-06-08$20.0MUndisclosedArticle
2016-05-27$51.2MUndisclosedFayerweather FundArticle
2016-07-14$12.5MUndisclosedFayerweather FundArticle